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Introduction
Anti-CD19 chimeric antigen receptor T cells (CART19)
and bi-specific anti-CD19/CD3 antibodies (blinatumo-
mab) are generating unprecedented complete responses
in relapsing/refractory B-cell acute lymphoblastic leuke-
mia (r/r B-ALL). However, a subset of patients still
relapse and about 30-50% of these relapses are charac-
terized by the loss of detectable CD19 [1-3]. The inter-
leukin-3 receptor alpha, or CD123, was shown to be
expressed in several hematologic neoplasms, including
acute myeloid leukemia and more recently also B-ALL.
The goal of this study was to pre-clinically evaluate the
impact of targeting both CD19 and CD123 with chi-
meric antigen receptor T cells for the treatment and
prevention of CD19-negative relapses occurring after
CD19-directed therapies [4,5].
Results
CD123 expression was analyzed by flow cytometry in
36 r/r B-ALL samples: CD123 was highly expressed
(81.75%, range: 5.10-99.60), representing a promising
candidate for targeted therapy in B-ALL. Moreover,
CD123 was also found to be expressed in the putative
leukemia stem cells, identified as CD34-pos CD38-neg.
The expression of CD123 was detected in all (n=6)
CD19-negative B-ALL blasts analyzed after relapse from
CART19 treatment (representative case in Figure 1).
Therefore, we generated anti-CD123 chimeric antigen
receptor T cells co-stimulated with 4-1-BB using a lenti-
viral vector (CART123) [5]. We then evaluated the
CART123 anti-leukemia efficacy both in vitro and
in vivo against primary B-ALL blasts and the cell line
NALM-6. CART123 showed intense anti-leukemia activ-
ity, as defined by specific CD107a degranulation, cytokine
production, cytotoxicity and proliferation, not statistically
different from that of CART19. In order to test the role
of CART123 to target CD19- negative relapses we devel-
oped a novel in vivo model, engrafting immunodeficient
NSG mice with blasts from a patient relapsing with
CD19-negative disease after CART19 treatment. At day
14 mice were randomized to receive control T cells
(UTD), CART19, or CART123 in combination with
CART19. CART19 and control T cell treated mice
showed no anti-tumor activity, while CART123+CART19
led to complete eradication of the disease and long-term
survival (Figure 2).
Conclusions
Here we demonstrate that CD123 is expressed in CD19-
negative B-ALL relapses occurring after CD19-directed
therapies, and that combining CART123 cells with
CART19 cells is an effective therapy for the treatment
and prevention of antigen-loss relapses in B-ALL murine
xenografts.
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